Biocon founder Kiran Mazumdar-Shaw’s post on Bengaluru’s poor civic condition has stirred a debate within the Karnataka government. In her post, Shaw said an overseas business visitor to Biocon Park questioned why the city’s roads were in such bad shape and garbage was piling up. “Doesn’t the government want to support investment? I have just … Read more
Rajesh Palviya, Axis Securities, shared his outlook on the markets and trading strategies amid heightened volatility. He noted that uncertainty stemming from global cues, particularly comments from US President Trump, has kept investors cautious despite several reform-driven announcements from the Indian government. According to him, the Nifty has breached crucial support zones, specifically the 61% … Read more
Brokerages remain optimistic on select mid-to-large cap names, highlighting strong structural drivers and attractive valuations. Nuvama has initiated coverage on Eureka Forbes, Religare Broking has turned positive on REC Ltd, while Motilal Oswal reiterated its bullish stance on Biocon. The common thread across these calls is robust earnings visibility, leadership in core segments, and growth … Read more
Market Summary Indian market closed flat with a positive bias on Wednesday. The BSE Sensex rose more than 60 points while the Nifty50 closed above 25200 levels. Sectoral Summary Sectorally, buying was seen in auto, FMCG, realty, and IT stocks while selling was seen in healthcare, capital goods and metal stocks. Breakout Stocks Stocks that … Read more
The Indian market is likely to consolidate on Tuesday, tracking mixed global cues. The Nifty future closed negatively with losses of 0.20% at 25,173 levels on Monday. India VIX was up 1.3% to close at 11.98 in the previous session. On the options front, the maximum Call OI is at 25,500 and then at 25,300 … Read more
Biocon on Thursday said its board has approved to acquire 1.5% equity share capital for Rs 550 crore in Biocon Biologics, from one of its existing investors who decided to exercise the liquidity option, in an all cash deal. Post this purchase, Biocon’s stake in Biocon Biologics will be 90.2%. The purchase is expected to … Read more
“23,000 is a support level that we are looking at and on the upside 23,500 is the resistance that we are looking at. Although if it fails to hold 23,000, we could see a more downside move towards 22,650 levels. Now, this is the range and the band coming out for Nifty,” says Shivangi Sarda, … Read more
After BSE has announced that it will discontinue Bankex weekly expiries, the market is rife with speculations that NSE may choose Nifty Bank over Nifty as both exchanges have to pick one expiry under new Sebi rules. Nifty Bank brings in higher volumes for the exchange, and better trading opportunities for speculators, but if Nifty … Read more
“I think the time has come for them to really take charge or take lead or join the overall bullish camp and that is what is sort of happening. A lot of people have started to relook at HDFC Bank,” says Rohit Srivastava, Strike Money Analytics & Indiacharts.What are you reading of this kind of … Read more
Brokerage firm JPMorgan maintained an overweight rating on LIC Housing Finance, Nomura has a buy rating on Info Edge, BofA Securities recommended a buy on Biocon and Jefferies upgraded M&M to buy. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: JPMorgan on LIC Housing: Overweight| Target Rs … Read more